Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns

References

• WHO. Annual review of diseases prioritized under the Research and Development Blueprint. 2018.
   Google Scholar
• JHU. Covid-19 Global Cases by the Center for Systems Science and Engineering at JHU. [ cited 2020 Jun 6]. Available from: https://coronavirus.jhu.edu/map.html
   Google Scholar
• Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.
   PubMed Web of Science ®Google Scholar
• WHO. DRAFT landscape of COVID-19 candidate vaccines – 20 March 2020. 2020.
   Google Scholar
• LSHTM. COVID-19 vaccine development pipeline. [ cited 2020 Jun 6]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/
   Google Scholar
• WHO. WHO R&D Blueprint - novel Coronavirus - COVID-19 Phase IIb/III Vaccine Trial Synopsis. 2020.
   Google Scholar
• CEPI/BC. Consensus considerations on the assessment of the risk of disease enhancement with COVID-19 vaccines: outcome of a Coalition for Epidemic Preparedness Innovations (CEPI)/Brighton Collaboration (BC) scientific working meeting, March 12–13, 2020. 2020.
   Google Scholar
• ICMRA. Summary Report - Global regulatory workshop on COVID-19 vaccine development. 2020. Available from: http://icmra.info/drupal/sites/default/files/2020-03/First%20regulatory%20COVID-19%20workshop%20-%20meeting%20report_March%202020.pdf
   Google Scholar
• Huisman W, Martina BE, Rimmelzwaan GF, et al. Vaccine-induced enhancement of viral infections. Vaccine. 2009;27(4):505–512.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449–463.
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435–448.
   PubMed Web of Science ®Google Scholar
• Weibel RE, Stokes J Jr., Leagus MB, et al. Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966. Am Rev Respir Dis. 1967;96(4):724–739.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–421.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020;20(6):347–348.
   Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–946.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Pierson TC. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe. 2020;27(5):699–703.
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859–865.
   PubMed Web of Science ®Google Scholar
• Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity. 2019;51(3):429–442.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–340.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–1459.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Immune enhancement of viral infection. Prog Allergy. 1982;31:301–364.
   PubMedGoogle Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133:1015–1024.
   Web of Science ®Google Scholar
• Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421.
   PubMed Web of Science ®Google Scholar
• Iwata-Yoshikawa N, Uda A, Suzuki T, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014;88(15):8597–8614.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995–3007.
   PubMed Web of Science ®Google Scholar
• Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–12215.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–2356.
   PubMed Web of Science ®Google Scholar
• See RH, Petric M, Lawrence DJ, et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol. 2008;89(Pt 9):2136–2146.
   PubMed Web of Science ®Google Scholar
• Roberts A, Lamirande EW, Vogel L, et al. Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 2010;23(5):509–519.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832–2838.
   PubMed Web of Science ®Google Scholar
• Kam YW, Kien F, Roberts A, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729–740.
   PubMed Web of Science ®Google Scholar
• Deming D, Sheahan T, Heise M, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3(12):e525.
   PubMed Web of Science ®Google Scholar
• Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337–6348.
   PubMed Web of Science ®Google Scholar
• Hashem AM, Algaissi A, Agrawal AS, et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 mouse model. J Infect Dis. 2019;220(10):1558–1567.
   PubMed Web of Science ®Google Scholar
• Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17–18):2273–2279.
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676.
   PubMed Web of Science ®Google Scholar
• Lamirande EW, DeDiego ML, Roberts A, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008;82(15):7721–7724.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4:4.
   Web of Science ®Google Scholar
• Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–9325.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fett C, Zhao J, et al. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034–11044.
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015;33(44):5920–5926.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020. DOI:10.1126/science.abc6284.
   Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020. DOI:10.1126/science.abc1932.
   Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;130:2620–2629. .
   Web of Science ®Google Scholar
• Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
   PubMed Web of Science ®Google Scholar
• Lv H, Wu NC, Tak-Yin Tsang O, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;107725:1-6.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280 e278.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;102434:1-6.
   Google Scholar
• Li CK-F, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490–5500.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036–1045 e1039.
   PubMed Web of Science ®Google Scholar
• Pedersen SF, Ho YC. SARS-CoV-2: A Storm is Raging. J Clin Invest. 2020;130:2202–2205.
   PubMed Web of Science ®Google Scholar
• Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc. 2020 Jul 13;9(3):393-398.DOI: 10.1093/jpids/piaa069.
   Web of Science ®Google Scholar
• Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608.
   PubMed Web of Science ®Google Scholar
• Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020;579(7799):321.
   PubMed Web of Science ®Google Scholar
• Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123–129.
   PubMed Web of Science ®Google Scholar
• Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus. Virology. 2015;479–480:247–258.
   PubMed Web of Science ®Google Scholar
• Callaway E. Labs rush to study coronavirus in transgenic animals - some are in short supply. Nature. 2020;579(7798):183.
   PubMed Web of Science ®Google Scholar
• Moorthy V, Henao Restrepo AM, Preziosi MP, et al. Data sharing for novel coronavirus (COVID-19). Bull World Health Organ. 2020;98(3):150.
   PubMed Web of Science ®Google Scholar
• Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum Vaccin Immunother. 2019;15(3):625–627.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Yoon IK. A review of Dengvaxia(R): development to deployment. Hum Vaccin Immunother. 2019;15(10):2295–2314.
   PubMed Web of Science ®Google Scholar
• WHO. Ten threats to global health in 2019. 2019.
   Google Scholar